Hi Paul!
You know most studies show that Vidaza is working in about 50% of the high risk patients.
In the low risk patients the results are very different - from more than 60% responding patients to a negative result. Here is a study from ASH from Korea
https://ash.confex.com/ash/2014/webp...aper72135.html. Eventually didn't the Vidaza patients get the best possible supportive therapy.
In EU Vidaza is not approved for low risk MDS.
Many low risk patients manage well with supportive therapy during many years while some patients have a more serious disease and should get a SCT early.
Kind regards
Birgitta-A
75 yo, dx MDS Interm-1 2006, tx dependent from dx with HGB 7.0 and very serious bone marrow fibrosis. Supportive therapy with txs, Neupogen for low WBC and iron chelators until 2010. Responded 3 years on Thalidomide and one year on Revlimid. Now tx dependent.